Tsuji T, Naito K, Tokuyama K, Okada T, Takata S, Araki K, Shinohara T, Inoue J, Onoue K, Tsuchiya M, Nozaki H, Nagashima H, Hamaya K
Hepatogastroenterology. 1980 Apr;27(2):85-90.
Follow-up studies were conducted on chronic liver disease patients treated 10 years previously with corticosteroid (CS), Hbs antigen (HbsAg) was measured in previously collected paraffin embedded liver sections by enzyme-labelled antibody technique. Of 57 cases examined, 38 cases were treated with CS or immunosuppressive agents and 19 cases were not treated with CS (control group). -- Two deaths occurred in the CS-treated group and 4 in the non-CS treated group. These patients were diagnosed as either the 2B type (severe activity) of chronic aggressive hepatitis (CAH) or as having liver cirrhosis. One death was found in the 10th year due to hepatocellular carcinoma in a chronic persistent hepatitis (CPH) patient with HBsAg diffusely distributed in liver tissue. No significant difference was found in the rehabilitation rate in HBsAg negative cases of the CS group versus the control group. In positive cases, the rehabilitation rate was found to be 66.7% in the CS group compared with 0% in the non-CS group.
对10年前接受过皮质类固醇（CS）治疗的慢性肝病患者进行了随访研究，采用酶标抗体技术在先前收集的石蜡包埋肝切片中检测乙肝表面抗原（HbsAg）。在检查的57例患者中，38例接受了CS或免疫抑制剂治疗，19例未接受CS治疗（对照组）。——CS治疗组有2例死亡，非CS治疗组有4例死亡。这些患者被诊断为慢性活动性肝炎（CAH）的2B型（重度活动）或肝硬化。一名慢性持续性肝炎（CPH）患者在第10年因肝细胞癌死亡，其肝组织中乙肝表面抗原弥漫分布。CS组与对照组乙肝表面抗原阴性病例的康复率无显著差异。在阳性病例中，CS组的康复率为66.7%，而非CS组为0%。
